Journal of Clinical Pathology最新文献_第7页

National Cancer Plan for England has landed: what does it mean for NHS histopathology? 英国国家癌症计划已经落地：这对NHS组织病理学意味着什么？

IF 2.6 4区医学

Journal of Clinical Pathology Pub Date : 2026-06-18 DOI: 10.1136/jcp-2026-210768

David Quane, Runjan Chetty

引用次数: 0

AI triage of duodenal biopsies improves workflow. 十二指肠活检的人工智能分诊改善了工作流程。

IF 2.6 4区医学

Journal of Clinical Pathology Pub Date : 2026-05-18 DOI: 10.1136/jcp-2026-210658

Frederick George Mayall, Charles Mayall, Ian Bodger, Henry Mayall

{"title":"AI triage of duodenal biopsies improves workflow.","authors":"Frederick George Mayall, Charles Mayall, Ian Bodger, Henry Mayall","doi":"10.1136/jcp-2026-210658","DOIUrl":"10.1136/jcp-2026-210658","url":null,"abstract":"Aims: To develop, deploy and evaluate artificial intelligence (AI) for triaging duodenal biopsies within a National Health Service (NHS) histopathology laboratory, with the aim of improving reporting turnaround times for clinically significant diagnoses.Methods: The pathway was developed in the UK in an NHS laboratory. Rule-based automation software was used to find all newly scanned duodenal biopsy slides. Those with case numbers ending in an odd number were exported for AI triage and if they had significant AI predicted abnormalities they were prioritised for reporting. The cases with even numbers followed the routine reporting pathway.Results: 313 cases (517 duodenal slides) were processed by the routine pathway, and 329 cases (533 duodenal slides) were processed by the AI triage pathway. AI processing took about 70 s per slide. The AI classifier had a sensitivity and positive predictive value (PPV) as follows: normal small bowel: 99.6%, 95.7%; coeliac disease: 86.7%, 100%; gastric heterotopia: 84.6%, 95.7%; adenoma: 88.9%, 88.9%; adenocarcinoma: 50.0%, 100%. In the AI triage workstream coeliac disease, and non-neoplastic abnormalities as a group, were reported quicker than in the standard workstream (6 days vs 10 days and 7 days vs 10 days, respectively, both p<0.005), but neoplastic lesions were not reported quicker. The cost of deployment and operation was reasonable.Conclusions: An NHS histopathology laboratory successfully developed and implemented an AI-based triage system for duodenal biopsies, achieving high diagnostic accuracy and significantly improving turnaround times for coeliac disease and non-neoplastic abnormalities as a group. This study demonstrates the feasibility and clinical value of locally developed AI tools within routine diagnostic practice.","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"380-388"},"PeriodicalIF":2.6,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147690263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Increased CD103+ T lymphocytes in lymph nodes as a marker of metastasis from non-haematopoietic malignancies. 淋巴结中CD103+ T淋巴细胞增加作为非造血恶性肿瘤转移的标志。

IF 2.6 4区医学

Journal of Clinical Pathology Pub Date : 2026-05-18 DOI: 10.1136/jcp-2026-210641

Mahboobsadat Hamidi, Jason E Love, Parham Minoo, Afshin Shameli

{"title":"Increased CD103+ T lymphocytes in lymph nodes as a marker of metastasis from non-haematopoietic malignancies.","authors":"Mahboobsadat Hamidi, Jason E Love, Parham Minoo, Afshin Shameli","doi":"10.1136/jcp-2026-210641","DOIUrl":"10.1136/jcp-2026-210641","url":null,"abstract":"Aims: To determine if the frequency of CD103+ T cells among background lymphocytes is associated with non-haematopoietic metastasis in samples of clinically concerning unexplained lymphadenopathy.Methods: We retrospectively reviewed clinical flow cytometry data from 126 lymph node (LN) samples including 36 involved by metastatic non-haematopoietic malignancy and 90 control LNs (54 benign/reactive and 36 lymphomas). We evaluated the frequency of CD103+ cells among CD3+, CD3+CD4+ and CD3+CD8+ T cell subsets. Immunohistochemistry was used to visualise CD103 expression in a limited number of cases.Results: CD103 expression in ≥3% of total CD3+ T cells and ≥7% of CD3+CD8+ T cells correlated with the presence of metastatic non-haematopoietic malignancy in LNs, and differentiated LNs with metastasis from control LNs with sensitivities of 75% (95% CI 59% to 86%) and 78% (95% CI 62% to 88%) and specificities of 100% (95% CI 96% to 100%) and 99% (95% CI 94% to 100%), respectively.Conclusion: Increased frequency of CD103+ T cells is associated with metastatic non-haematopoietic malignancies in excisional and core needle biopsies of clinically concerning lymphadenopathy.","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"404-409"},"PeriodicalIF":2.6,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147633671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinicopathological and molecular characterisation of superficial CD34-positive fibroblastic tumour: A systematic review. 浅表cd34阳性纤维母细胞瘤的临床病理和分子特征：系统综述。

IF 2.6 4区医学

Journal of Clinical Pathology Pub Date : 2026-05-18 DOI: 10.1136/jcp-2025-210391

Sumanta Das, Raul Perret, Adil Aziz Khan, Pallavi Mishra, Sunita Ahlawat

{"title":"Clinicopathological and molecular characterisation of superficial CD34-positive fibroblastic tumour: A systematic review.","authors":"Sumanta Das, Raul Perret, Adil Aziz Khan, Pallavi Mishra, Sunita Ahlawat","doi":"10.1136/jcp-2025-210391","DOIUrl":"10.1136/jcp-2025-210391","url":null,"abstract":"Aim: This systematic review aims to comprehensively evaluate the clinicopathological and molecular features of superficial CD34-positive fibroblastic tumour (SCD34FT), a recently described intermediate-grade soft-tissue neoplasm recognised in the 5th edition of the WHO classification of soft tissue tumours.Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, we systematically searched for English-language studies in PubMed, Scopus, Google Scholar and Web of Science. Retrospective or original case series with ≥3 histologically confirmed cases were selected for review, whereas review articles, single case reports and conference abstracts were excluded. Risk of bias was assessed using the Joanna Briggs Institute checklist.Results: A total of 190 patients across 14 selected studies met the inclusion criteria. SCD34FT mainly affected middle-aged adults, with the most common site being the lower extremity. Diffuse CD34 expression was universal across all studies. A high number of cases displayed SynCAM/CADM3 positivity, while WT1 and Pan-CK (focal) were frequent. PRDM10 fusion was detected in 73% of cases, and the most common fusions were PRDM10::MED12 (66%) and PRDM10::CITED2 (28%). Only 9/169 (5.3%) had local recurrences, whereas 4/190 (2.1%) cases had lymph node metastasis, with no distant metastasis or disease-related death.Conclusion: SCD34FT is a novel entity with consistent CD34 expression and recurrent PRDM10 rearrangements and shows indolent behaviour. A high index of suspicion for SCD34FT should be warranted in a superficially located tumour with striking nuclear pleomorphism but an unexpectedly low mitotic index. Molecular studies demonstrating PRDM10 rearrangement may be helpful in atypical cases.","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"373-379"},"PeriodicalIF":2.6,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147662805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute onset severe hypophosphataemia in transformed acute myeloid leukaemia: an unusual biochemical presentation. 转化型急性髓性白血病急性发作严重低磷血症:一种不寻常的生化表现。

IF 2 4区医学

Journal of Clinical Pathology Pub Date : 2026-05-18 DOI: 10.1136/jcp-2023-208907

Catelyn Cashion, Paul Bonnitcha, William Stevenson

引用次数: 0

Proposals to make diagnostic criteria truly usable and useful to pathologists worldwide. 建议使诊断标准对全世界的病理学家真正可用和有用。

IF 2 4区医学

Journal of Clinical Pathology Pub Date : 2026-05-18 DOI: 10.1136/jcp-2025-210281

Philippe Benjamin Stephenson, Olaleke Folaranmi, José Jiménez Heffernan, Sanjay Mukhopadhyay

引用次数: 0

MYD88 gene and protein: molecular architecture, signalling mechanisms and clinical implications in lymphoid malignancies. MYD88基因和蛋白：淋巴细胞恶性肿瘤的分子结构、信号传导机制和临床意义。

IF 2.6 4区医学

Journal of Clinical Pathology Pub Date : 2026-05-18 DOI: 10.1136/jcp-2026-210690

Sukanya Banerjee Nair, Teresa S Hyun, Kikkeri N Naresh

{"title":"MYD88 gene and protein: molecular architecture, signalling mechanisms and clinical implications in lymphoid malignancies.","authors":"Sukanya Banerjee Nair, Teresa S Hyun, Kikkeri N Naresh","doi":"10.1136/jcp-2026-210690","DOIUrl":"10.1136/jcp-2026-210690","url":null,"abstract":"MYD88 is a signal-transducing adaptor protein that plays a central role in Toll-like receptor and interleukin 1 receptor signalling through activation of the NF-κB pathway. The somatic L265P mutation in MYD88 represents a recurrent gain-of-function alteration in mature B-cell neoplasms, most notably lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinaemia (WM) (>90%), IgM monoclonal gammopathy of undetermined significance (27%-87%) and activated B-cell-type diffuse large B-cell lymphoma (DLBCL), particularly those arising in immune-privileged sites such as the central nervous system (CNS) and testis. The L265P substitution promotes constitutive myddosome assembly, IRAK1/4 recruitment and aberrant Bruton tyrosine kinase (BTK) activation, resulting in sustained NF-κB signalling independent of receptor engagement. Concurrent mutations-including CXCR4 in LPL and CD79B in DLBCL-define distinct molecular subtypes with prognostic and therapeutic implications. MYD88 mutation status serves as a valuable diagnostic biomarker, aiding differentiation of LPL from morphological mimics and enabling liquid biopsy approaches in primary CNS lymphoma. The prognostic significance of L265P is context-dependent: it confers favourable outcomes in WM but portends inferior survival in DLBCL. Therapeutically, MYD88 L265P predicts response to BTK inhibitors in WM, although concurrent CXCR4 mutations attenuate treatment efficacy. Detection methodologies include allele-specific PCR for targeted L265P detection and next-generation sequencing for comprehensive mutational profiling. This review summarises the molecular biology, disease associations, clinical utility and therapeutic implications of MYD88 mutations in lymphoid malignancies.","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"363-369"},"PeriodicalIF":2.6,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Malignant effusions serve as a feasible source for therapy-related biomarker testing in advanced gastric cancer. 恶性积液可作为晚期胃癌治疗相关生物标志物检测的可行来源。

IF 2.6 4区医学

Journal of Clinical Pathology Pub Date : 2026-05-18 DOI: 10.1136/jcp-2026-210622

Wenhao Ren, Qian Wang, Yiyi Guo, Haizhu Jin, Xiuli Ma, Yanli Zhu

{"title":"Malignant effusions serve as a feasible source for therapy-related biomarker testing in advanced gastric cancer.","authors":"Wenhao Ren, Qian Wang, Yiyi Guo, Haizhu Jin, Xiuli Ma, Yanli Zhu","doi":"10.1136/jcp-2026-210622","DOIUrl":"10.1136/jcp-2026-210622","url":null,"abstract":"Aims: Malignant effusion is a common manifestation of metastatic gastric cancer. This study compared the expression of key biomarkers (human epidermal growth factor receptor 2 (HER2), programmed cell death ligand 1 (PD-L1), claudin 18.2 (CLDN18.2) and fibroblast growth factor receptor 2b (FGFR2b)) between malignant effusion-derived cell blocks (CBs) and matched primary or metastatic tumour tissues and evaluated the longitudinal concordance of biomarker expression in serially collected CBs.Methods: Biomarker status was retrospectively assessed by immunohistochemistry in CBs from malignant effusions and paired primary/metastatic gastric adenocarcinomas. HER2+ cases underwent fluorescence in situ hybridisation to confirm amplification.Results: CLDN18.2 showed the highest positivity rate (34.0%). PD-L1 expression was positive in 8.6% of tumours and 13.9% of stroma. Lower rates were observed for FGFR2b (3.8%) and HER2 (3.3%). FGFR2b positivity was more frequent in CBs than in primary tumours (p=0.044) with higher expression levels (p=0.02). Conversely, CLDN18.2 positivity was lower in CBs versus primary tumours (p=0.004). Metastatic lesions showed higher CLDN18.2 positivity (p=0.04) and expression levels (p=0.002) compared with CBs. Serial CB analysis revealed high concordance rates: FGFR2b (99.1%), HER2 (98.1%), tumour PD-L1 (94.8%) and CLDN18.2 (92.2%).Conclusions: Malignant effusion CBs show favourable intra-patient biomarker consistency over time, supporting their feasibility for longitudinal monitoring. Effusion-based testing shows potential value for potentially identifying candidates for FGFR2b-targeted therapies, pending further clinical validation.","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"410-417"},"PeriodicalIF":2.6,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147609084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Keratin 7 immunohistochemistry reveals patterns of cell populations in liver biopsies from patients with MASLD. 角蛋白7免疫组化揭示了MASLD患者肝活检细胞群的模式。

IF 2.6 4区医学

Journal of Clinical Pathology Pub Date : 2026-05-18 DOI: 10.1136/jcp-2025-210592

Leana Ducor, Montserrat Fraga, Rita Manco, Elise Mdawar-Bailly, Joana Vieira, Christine Sempoux, Pierre Moulin

{"title":"Keratin 7 immunohistochemistry reveals patterns of cell populations in liver biopsies from patients with MASLD.","authors":"Leana Ducor, Montserrat Fraga, Rita Manco, Elise Mdawar-Bailly, Joana Vieira, Christine Sempoux, Pierre Moulin","doi":"10.1136/jcp-2025-210592","DOIUrl":"10.1136/jcp-2025-210592","url":null,"abstract":"Aims: Metabolic-associated steatotic liver disease (MASLD), which encompasses metabolic associated steatotic liver (MASL) and metabolic-associated steatohepatitis (MASH), is the most common chronic liver disorder worldwide. Fibrosis stage remains the most dependable histological predictor of prognosis; however, routine stains do not fully capture regenerative and injury-related processes. Keratin 7 (K7) immunohistochemistry highlights bile ducts (BDs), ductular reaction (DR), hepatic progenitor cells (PCs) and intermediate hepatocytes (IHs), all of which are involved in regeneration and fibrogenesis. This study aims to quantify K7-positive cell populations across histological stages of MASLD to enhance disease characterisation and evaluate the diagnostic value of K7 immunohistochemistry in this setting.Methods: Archived liver biopsies from a clinically well-characterised cohort of 36 patients (17 MASH, 19 MASL) were stained for K7, digitised and analysed using QuPath with manual expert review. K7-positive structures were classified into BD, DR, PC or IH, with over 10 000 objects quantified. Profile densities and portal tract normalised ratios were calculated and correlated with clinical, biochemical and histological grading and staging by the Steatosis Activity and Fibrosis score.Results: PC showed the strongest association with necro-inflammatory activity, peaking at grade 3. DR density increased significantly with fibrosis, supporting its role as an early marker of disease progression. IH was notably higher in MASH than in MASL, resulting in higher IH/DR ratios.Conclusion: Specific quantitation of K7-positive cell populations can refine the diagnosis of MASLD and complement routine scoring in clinical trials to improve patient stratification.","PeriodicalId":15391,"journal":{"name":"Journal of Clinical Pathology","volume":" ","pages":"389-395"},"PeriodicalIF":2.6,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147512446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrated histomolecular diagnosis of mesenteric anisakiasis. 肠系膜异歧虫病的综合组织分子诊断。

IF 2.6 4区医学

Journal of Clinical Pathology Pub Date : 2026-05-18 DOI: 10.1136/jcp-2026-210635

Emilie Kariya, Pauline Tirard-Collet, Camille Boulagnon-Rombi, Gregory Destras, Martine Wallon, Jean Menotti, Audrey Lapendry, Nedjma Kaidi, Meja Rabodonirina, Loïc Lievre, Jérôme Depaquit, Isabelle Villena, Alexis Trecourt, Antoine Huguenin

引用次数: 0